Soligenix Announces Commercial Collaboration with SciClone Pharmaceuticals in China for SGX942 in the Treatment of Oral

Soligenix Announces Commercial Collaboration with SciClone Pharmaceuticals in
             China for SGX942 in the Treatment of Oral Mucositis

Access to SciClone Oral Mucositis Clinical Data Enables Personalized Medicine
Approach for Design of Clinical Trials

PR Newswire

PRINCETON, N.J., July 8, 2013

PRINCETON, N.J., July 8, 2013 /PRNewswire/ --Soligenix, Inc. (OTCQB: SNGX)
(Soligenix or the Company), a clinical stage biopharmaceutical company focused
on developing products to treat inflammatory diseases and biodefense
countermeasures where there remains an unmet medical need, announced a
personalized medicine collaboration with SciClone Pharmaceuticals in the
Company's oral mucositis clinical program with SGX942. As part of this
collaboration, Soligenix will receive access to SciClone's oral mucositis
clinical and regulatory data library in exchange for commercialization rights
in the People's Republic of China, including Hong Kong and Macau. Specific
deal terms have not been disclosed at this time.

Soligenix is developing SGX942, an innate defense regulator, for the treatment
of oral mucositis (OM). OM in solid tumor patients, especially those with
head and neck cancer, is an area of unmet medical need, with no approved drug
therapy. It is estimated that OM affects approximately 90,000 head and neck
cancer patients per year in the US. SGX942 recently received investigational
new drug (IND) clearance from the US Food and Drug Administration (FDA) and is
poised to start a Phase 2 clinical trial by the end of the year.

SciClone completed two sequential Phase 2 clinical studies in 2010 and 2012
evaluating its drug, SCV-07, for the treatment of OM caused by chemoradiation
therapy in head and neck cancer patients, before terminating its program. As
this is the same population that Soligenix is pursuing for its OM program,
this information has the potential to increase the probability of success of
its upcoming Phase 2 clinical study. By analyzing data available from the
placebo subjects in the SciClone trials, Soligenix will acquire essential
insight into disease progression, along with quantitative understanding of its
incidence and severity in this patient population. This has the potential to
enable the design of the SGX942 clinical trials to be optimized and may allow
for novel and more robust response criteria to be defined. In addition,
analysis of blood samples from these subjects has the potential to identify
key biomarkers that could enable development of a prognostic enrichment tool
capable of predicting patients expected to develop severe OM on the basis of
their deoxyribonucleic acid (DNA) signature. The ability to identify the
patient population most likely to develop severe disease increases the
likelihood of observing a treatment response.

"This collaboration is unique in that it is the first time that a personalized
medicine approach has been comprehensively integrated with an oral mucositis
development program," stated Christopher J. Schaber, PhD, President and Chief
Executive Officer of Soligenix. "The extension of these biomarker approaches
in the SGX942 clinical trials also has the potential to form the basis of a
predictive enrichment tool and companion diagnostic to identify patients more
likely to respond to SGX942 treatment, thereby increasing the likelihood of
program success. We feel strongly that personalized treatment approaches are
best for patients, physicians and the healthcare system."

Dr. Schaber continued, "Our collaboration with SciClone is an ideal match.
SciClone has a significant commercial presence and expertise in China, and
their clinical and regulatory contribution to the SGX942 OM program has the
potential to accelerate development while dramatically improving clinical

The FDA has been an enthusiastic advocate of enrichment strategies. As
Margaret Hamburg, MD, Commissioner, US FDA remarked at the Personalized
Medicine Coalition's Sixth Annual Keynote Luncheon in February 25, 2010,
"…tailoring medicine such that the right therapies are delivered to the right
people is likely to be one of the most important themes for healthcare of the
future. The concept of personalized medicine is the understanding that people
differ in their genetic makeup, their environment and their lifestyle and that
these differences are critical factors in the severity and type of disease and
how individuals respond to therapies."

Recently this enthusiasm was reiterated by Robert Temple, MD, Deputy Director
for Clinical Science in FDA's Center for Drug Evaluation and Research in a
posting by the FDA Voice on December 17, 2012, in which he commented that
techniques for clinical trial enrichment, "…are potentially powerful
strategies for the pharmaceutical industry because appropriate use of
enrichment could result in smaller studies, shortened drug development times,
and lower development costs."

About SGX942

SGX942 is an innate defense regulator (IDR), a new class of short, synthetic
peptides that has a novel mechanism of action in that it has simultaneous
anti-inflammatory and anti-infective activity. IDRs have no direct antibiotic
activity but modulate host responses, increasing survival after infections
with a broad range of bacterial Gram-negative and Gram-positive pathogens, as
well as accelerating resolution of tissue damage following exposure to a
variety of agents including bacterial pathogens, trauma and chemo- and/or
radiation-therapy. SGX942 has demonstrated safety in a Phase 1 clinical study
in healthy human volunteers and efficacy in numerous animal disease models
including mucositis, colitis, skin infection and other bacterial infections.
SGX942 was developed pursuant to discoveries made by Professors B. Brett
Finlay, PhD and Robert Hancock, PhD of the University of British Columbia,
Canada and approximately $40 million has been put towards its development to
date, inclusive of government grants.

About Oral Mucositis

Mucositis is the clinical term for damage done to the mucosa by anticancer
therapies. It can occur in any mucosal region, but is most commonly associated
with the mouth, followed by the small intestine. It is estimated, based upon
review of historic published studies and reports and an interpolation of data
on the incidence of mucositis, that mucositis affects approximately 500,000
people in the US per year and occurs in 40% of patients receiving
chemotherapy. Mucositis can be severely debilitating and can lead to
infection, sepsis, the need for parenteral nutrition and narcotic analgesia.
The gastro-intestinal damage causes severe diarrhea. These symptoms can limit
the doses and duration of cancer treatment, leading to sub-optimal treatment

The mechanisms of mucositis have been extensively studied and have been
recently linked to the interaction of chemotherapy and/or radiation therapy
with the innate defense system. Bacterial infection of the ulcerative lesions
is now regarded as a secondary consequence of dysregulated local inflammation
triggered by therapy-induced cell death, rather than as the primary cause of
the lesions.

It is estimated, based upon review of historic published studies and reports
and an interpolation of data on the incidence of oral mucositis, that oral
mucositis is a subpopulation of approximately 90,000 patients in the US, with
a comparable number in Europe.Oral mucositis almost always occurs in
patients with head and neck cancer treated with radiation therapy (>80%
incidence of severe mucositis) and is common (40-100% incidence) in patients
undergoing high dose chemotherapy and hematopoietic cell transplantation,
where the incidence and severity of oral mucositis depends greatly on the
nature of the conditioning regimen used for myeloablation.

About SciClone Pharmaceuticals Inc.

SciClone Pharmaceuticals is a US-based, China-focused specialty pharmaceutical
company with a product portfolio of therapies for oncology, infectious
diseases and cardiovascular, urological, respiratory, and central nervous
system disorders. SciClone's ZADAXIN^® (thymalfasin) is approved in over 30
countries and may be used for the treatment of hepatitis B (HBV), hepatitis C
(HCV) and certain cancers, and as a vaccine adjuvant, according to the local
regulatory approvals. Besides ZADAXIN, SciClone markets about 14 mostly
partnered products in China, including Depakine®, the most widely prescribed
broad-spectrum anti-convulsant in China; Tritace®, an ACE inhibitor for the
treatment of hypertension; Stilnox®, a leading hypnotic for the short-term
treatment of insomnia (marketed as Ambien® in the US); and Aggrastat®, a
recently-launched interventional cardiology product. SciClone is also pursuing
the registration of several other therapeutic products in China. SciClone is
headquartered in Foster City, California. For additional information, please

About Soligenix, Inc.

Soligenix is a clinical stage biopharmaceutical company developing products to
treat serious inflammatory diseases where there remains an unmet medical need,
as well as developing several biodefense vaccines and therapeutics. Soligenix
is developing proprietary formulations of oral BDP (beclomethasone
17,21-dipropionate) for the prevention/treatment of gastrointestinal disorders
characterized by severe inflammation, including pediatric Crohn's disease
(SGX203), acute radiation enteritis (SGX201) and chronic Graft-versus-Host
disease (orBec^®), as well as developing its novel innate defense regulator
(IDR) technology SGX942 for the treatment of oral mucositis.

Through its BioDefense Division, Soligenix is developing countermeasures
pursuant to the Biomedical Advanced Research and Development Authority (BARDA)
Strategic Plan of 2011-2016 for inclusion in the US government's Strategic
National Stockpile. Soligenix's lead biodefense products in development are a
recombinant subunit vaccine called RiVax™, which is designed to protect
against the lethal effects of exposure to ricin toxin and VeloThrax™, a
vaccine against anthrax exposure. RiVax™ has been shown to be well tolerated
and immunogenic in two Phase 1 clinical trials in healthy volunteers. Both
RiVax™ and VeloThrax™ are currently the subject of a $9.4 million National
Institute of Allergy and Infectious Diseases (NIAID) grant supporting
development of Soligenix's new vaccine heat stabilization technology known as
ThermoVax™. Soligenix is also developing OrbeShield™ for the treatment of
gastrointestinal acute radiation syndrome (GI ARS) under a $600,000 NIAID
Small Business Innovation Research (SBIR) grant. OrbeShield™ has previously
demonstrated statistically significant preclinical survival results in two
separate canine GI ARS studies funded by the NIAID. Recently, Soligenix
announced a worldwide exclusive collaboration with Intrexon Corporation that
will focus on the joint development of a treatment for Melioidosis, a high
priority biothreat and an area of unmet medical need.

For further information regarding Soligenix, Inc., please visit the Company's
website at

This press release contains forward-looking statements that reflect Soligenix,
Inc.'s current expectations about its future results, performance, prospects
and opportunities, including but not limited to, potential market sizes,
patient populations and clinical trial enrollment. Statements that are not
historical facts, such as "anticipates," "estimates," "believes," "intends,"
"potential," or similar expressions, are forward-looking statements. These
statements are subject to a number of risks, uncertainties and other factors
that could cause actual events or results in future periods to differ
materially from what is expressed in, or implied by, these statements.
Soligenix cannot assure you that it will be able to successfully develop,
achieve regulatory approval for or commercialize products based on its
technologies, particularly in light of the significant uncertainty inherent in
developing vaccines against bioterror threats conducting preclinical and
clinical trials of vaccines, obtaining regulatory approvals and manufacturing
vaccines, that product development and commercialization efforts will not be
reduced or discontinued due to difficulties or delays in clinical trials or
due to lack of progress or positive results from research and development
efforts, that it will be able to successfully obtain any further funding to
support product development and commercialization efforts, including grants
and awards, maintain its existing grants which are subject to performance,
enter into any biodefense procurement contracts with the US Government or
other countries, that it will be able to compete with larger and better
financed competitors in the biotechnology industry, that changes in health
care practice, third party reimbursement limitations and Federal and/or state
health care reform initiatives will not negatively affect its business, or
that the US Congress may not pass any legislation that would provide
additional funding for the Project BioShield program. These and other risk
factors are described from time to time in filings with the Securities and
Exchange Commission, including, but not limited to, Soligenix's reports on
Forms 10-Q and 10-K. Unless required by law, Soligenix assumes no obligation
to update or revise any forward-looking statements as a result of new
information or future events.

SOURCE Soligenix, Inc.

Contact: Joe Warusz, CPA, Acting Chief Financial Officer, Soligenix, Inc.,
(609) 538-8200
Press spacebar to pause and continue. Press esc to stop.